- Home
- CATO vs BNTC Comparison
CATO vs BNTC Comparison
Compare CATO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- BNTC
- Stock Information
- Founded
- CATO 1946
- BNTC 1995
- Country
- CATO United States
- BNTC United States
- Employees
- CATO N/A
- BNTC N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- BNTC Health Care
- Exchange
- CATO Nasdaq
- BNTC Nasdaq
- Market Cap
- CATO 70.0M
- BNTC 88.1M
- IPO Year
- CATO N/A
- BNTC N/A
- Fundamental
- Price
- CATO $3.96
- BNTC $11.41
- Analyst Decision
- CATO
- BNTC Buy
- Analyst Count
- CATO 0
- BNTC 6
- Target Price
- CATO N/A
- BNTC $23.83
- AVG Volume (30 Days)
- CATO 350.0K
- BNTC 81.6K
- Earning Date
- CATO 11-21-2024
- BNTC 02-11-2025
- Dividend Yield
- CATO 17.44%
- BNTC N/A
- EPS Growth
- CATO N/A
- BNTC N/A
- EPS
- CATO N/A
- BNTC N/A
- Revenue
- CATO $666,779,000.00
- BNTC N/A
- Revenue This Year
- CATO N/A
- BNTC N/A
- Revenue Next Year
- CATO N/A
- BNTC N/A
- P/E Ratio
- CATO N/A
- BNTC N/A
- Revenue Growth
- CATO N/A
- BNTC N/A
- 52 Week Low
- CATO $3.02
- BNTC $2.69
- 52 Week High
- CATO $7.80
- BNTC $13.29
- Technical
- Relative Strength Index (RSI)
- CATO 44.65
- BNTC 51.22
- Support Level
- CATO $3.29
- BNTC $11.62
- Resistance Level
- CATO $4.29
- BNTC $13.29
- Average True Range (ATR)
- CATO 0.32
- BNTC 1.08
- MACD
- CATO 0.14
- BNTC 0.04
- Stochastic Oscillator
- CATO 60.48
- BNTC 50.53
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories primarily in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.